DailyIQ
|
Sector:HealthcareAll sectors
Last updated 7 minutes ago

ABT·Abbott Laboratories

$.
-. (-.%)
After Hours
High
$95.00
Open
$94.97
Market Cap
164.03B
52W High
$137.49
Low
$93.46
P. Close
$93.93
P/E
26.14
52W Low
$81.97
Fwd P/E
15.51
DailyIQ Est.
$120.12
Technical Score (1D)
55
BUY
News Sentiment
70
BULLISH
Abbott Laboratories has confirmed its 2.64 % dividend yield, backed by sustained profitability and a decade of growth, reinforcing its status as a reliable income generator. The company’s P/E ratio of 18.12 positions it favorably among peers, suggesting modest valuation relative to earnings potential. This stability in dividend policy signals that the firm is likely to maintain or modestly increase payouts in the near term, which can attract income‑focused investors. For the next 1–10 trading days, the market may react to any early earnings guidance or dividend adjustment announcements, as such changes could alter the perceived risk‑return profile. Watch for the upcoming earnings release, where management may provide updated revenue forecasts or cost‑control measures that could influence dividend sustainability. Additionally, monitor any regulatory updates or changes in healthcare reimbursement that could impact Abbott’s product mix and profitability. A shift in macroeconomic conditions, such as interest rate moves, could affect the attractiveness of the dividend yield relative to fixed‑income alternatives. Keep an eye on analyst revisions to the company’s valuation, as upgrades or downgrades may prompt short‑term price swings. Should Abbott announce a dividend hike or mandate a higher payout ratio, the stock could see a rally among income investors. Conversely, a cut or a warning about future payouts would likely trigger a sell‑off, so the next earnings call is the key watch item.
Earnings Summary
Abbott Laboratories, a global healthcare company founded in 1888, operates across established pharmaceuticals, diagnostics, nutritionals, and medical devices, positioning it within the broader medical devices sector. In the most recent two quarters, Abbott reported EPS of $1.50 in Q4 2025 and $1.15 in Q1 2026, averaging $1.33, slightly higher than the $1.28 average of Q2 2025 ($1.26) and Q3 2025 ($1.30); revenue rose from $11.142 B in Q2 2025 to $11.164 B in Q1 2026, up from an average of $11.256 B in the preceding two quarters, indicating modest acceleration. The company has beaten analyst estimates in three of the last four quarters, with Q2 2025, Q3 2025, and Q1 2026 exceeding forecasts, while Q4 2025 fell short on EPS and revenue. Historically, Abbott has shown a steady upward trajectory in revenue, moving from $10.974 B in Q4 2024 to $11.164 B in Q1 2026, and has consistently outperformed earnings expectations, though occasional misses like Q4 2025 suggest volatility around seasonal product cycles. Recent developments include the acquisition of Exact Sciences, which is expected to boost the cancer diagnostics segment, a Buy rating upgrade by Baird citing strong cash flow and ROIC, and the DOJ’s closure of its criminal probe into the Michigan baby‑formula plant, reducing regulatory risk; additionally, the partnership with Tandem Diabetes Care to integrate the FreeStyle Libre 3 Plus sensor expands Abbott’s diabetes ecosystem. Investors should watch the Q2 2026 earnings release for guidance confirmation, the progress of Exact Sciences integration, any civil penalties from the DOJ, and the market uptake of the Libre 3 Plus/Tandem partnership, as these factors will shape the company’s near‑term revenue momentum and valuation.

EPS

EstBeatMiss
$1.01$1.15$1.29$1.43$1.58Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.28 - -
Q1'26$1.15$1.15+0.3%
Q4'25$1.51$1.50-0.8%
Q3'25$1.30$1.30+0.0%
Q2'25$1.26$1.26+0.3%
Q1'25$1.07$1.09+1.7%

Revenue

EstBeatMiss
$10.0B$10.8B$11.5B$12.2B$13.0BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$12.6B - -
Q1'26$11.0B$11.2B+1.5%
Q4'25$11.9B$11.5B-3.9%
Q3'25 - $11.4B -
Q2'25 - $11.1B -
Q1'25 - $10.4B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

ABT Stock Snapshot

ABT is currently trading at $94.15, giving Abbott Laboratories a market cap of 164.03B and a P/E ratio of 26.1. Today's range spans $93.46–$95.00, with shares opening at $94.97 and moving up $0.22 (0.2%) from the prior close. DailyIQ's technical score sits at 55/100 (HOLD) with a news sentiment reading of 70/100.

Over the past year ABT has traded between $81.97 and $137.49 - the current price is +14.9% off the 52-week low and -31.5% from the high. 37 analysts cover the stock with a Buy consensus and a mean 12-month target of $116.40 (range $92.00–$135.00), implying upside of +23.6%.

Sector rotation context matters for ABT's HOLD phase (55/100, HOLD): in Healthcare, large-cap names (164.03B market cap) with neutral technicals and bullish sentiment (70/100) are often in a staging area ahead of a rotation trade. The current P/E ratio stands at 26.1. Price: $94.15 (in the lower half of its 52-week range in $81.97–$137.49). When sector flows resume, names that consolidated cleanly rather than correcting sharply tend to lead the next leg - and ABT's current setup fits that pattern.

The 52-week range of $81.97–$137.49 for ABT provides the structural reference that options traders, systematic funds, and discretionary managers all anchor to — and at $94.15 (in the lower half of its 52-week range), the stock sits in a zone where the next 5–10% move will likely define which crowd was right. A HOLD signal at 55/100 and bullish news backdrop (70/100) don't break the tie yet, but they narrow the probability distribution toward the upside.